Theremia develops advanced digital therapeutics designed to treat neurological and psychiatric disorders through personalized, non-invasive neuromodulation. The platform utilizes proprietary algorithms to deliver precise electrical stimulation, optimizing patient outcomes for conditions like depression and chronic pain. This approach offers a scalable, accessible alternative to traditional pharmacological interventions in mental healthcare.
Funding
$6.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
A+2Founders
Product
Problem
Current clinical trials often fail to account for the diverse needs of various patient demographics, leading to imprecise outcomes and delayed market access for pharmaceutical products. This lack of tailored treatment approaches can result in reduced drug efficacy and increased side effects in specific population subgroups.
Solution
Theremia offers an AI-driven platform designed to enhance drug efficacy and minimize side effects by tailoring treatments to the specific needs of diverse patient demographics. The platform refines clinical trial processes to ensure more precise and effective outcomes, accelerating the path to market for pharmaceutical products. By analyzing patient data and identifying unique characteristics within subgroups, Theremia's solution supports the development of personalized treatment plans. This approach promotes better health outcomes and optimizes drug performance across different populations.
Target Audience
Theremia's primary customers are pharmaceutical companies and clinical research organizations seeking to improve drug efficacy, reduce side effects, and accelerate market access through tailored treatment approaches.
Features
- AI-driven platform for tailoring treatments to diverse patient demographics.
- Refined clinical trial processes for more precise and effective outcomes.
- Identification of unique characteristics within patient subgroups.
- Personalized treatment plans based on patient data analysis.
- Support for patent extension strategies.